Close Menu

SoftGenetics

The integrated products will provide a seamless workflow for interpreting next-generation sequence data from alignment through pathway analysis.

SoftGenetics said this week that its GeneMarker Human Identity software has received NDIS approval from the Federal Bureau of Investigation.

CollabRx has launched CancerRx, a new oncology application that runs on Apple's operating system. The app provides oncologists and pathologists with treatment options that are based on their patients' tumors and also offers a daily newsfeed from MedPage Today.

The National Center for Biotechnology Information has updated its Sequence Viewer tool.

Genedata has released a new version of Genedata Expressionist for Mass Spectrometry, its software for the analyzing metabolomics data.
Version 8.0 includes new workflows for integrated processing of LC- and GC-MS data.

Foundation Medicine has launched FoundationOne Heme, a next-generation sequencing-based test that looks for genomic alterations in 405 genes related to hematological cancers. The test also incorporates RNA sequencing of 265 genes to look for gene fusions.

SoftGenetics has released the latest version of its NextGene software for analyzing next-generation sequence data.

NuGen Technologies has launched its Ovation Human FFPE RNA-seq Multiplex System, which provides an end-to-end solution for strand-specific RNA-seq library prep from formalin-fixed paraffin-embedded tissue.

SoftGenetics has added a copy number variation tool to its NextGene software.

Pages

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.